Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study

被引:104
|
作者
Falcone, Marco [1 ]
Tiseo, Giusy [1 ]
Giordano, Cesira [2 ]
Leonildi, Alessandro [1 ]
Menichini, Melissa [2 ]
Vecchione, Alessandra [2 ]
Pistello, Mauro [3 ,4 ]
Guarracino, Fabio [5 ]
Ghiadoni, Lorenzo [6 ]
Forfori, Francesco [7 ]
Barnini, Simona [2 ]
Menichetti, Francesco [1 ]
机构
[1] Univ Pisa, Dept Clin & Expt Med, Infect Dis Unit, Pisa, Italy
[2] Azienda Osped Univ Pisana, Microbiol Unit, Pisa, Italy
[3] Univ Pisa, Virol Unit, Dept Lab Med, Pisa Univ Hosp, Pisa, Italy
[4] Univ Pisa, Retrovirus Ctr, Dept Translat Res, Pisa, Italy
[5] Azienda Osped Univ Pisana, Dept Anaesthesia & Crit Care Med, Pisa, Italy
[6] Univ Pisa, Dept Clin & Expt Med, Emergency Med Unit, Pisa, Italy
[7] Univ Pisa, Dept Surg Med & Mol Pathol & Crit Care Med, Pisa, Italy
关键词
D O I
10.1093/jac/dkaa530
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Bacterial and fungal superinfections may complicate the course of hospitalized patients with COVID-19. Objectives: To identify predictors of superinfections in COVID-19. Methods: Prospective, observational study including patients with COVID-19 consecutively admitted to the University Hospital of Pisa, Italy, between 4 March and 30 April 2020. Clinical data and outcomes were registered. Superinfection was defined as a bacterial or fungal infection that occurred >= 48 h after hospital admission. A multivariate analysis was performed to identify factors independently associated with superinfections. Results: Overall, 315 patients with COVID-19 were hospitalized and 109 episodes of superinfections were documented in 69 (21.9%) patients. The median time from admission to superinfection was 19 days (range 11-29.75). Superinfections were caused by Enterobacterales (44.9%), non-fermenting Gram-negative bacilli (15.6%), Gram-positive bacteria (15.6%) and fungi (5.5%). Polymicrobial infections accounted for 18.3%. Predictors of superinfections were: intestinal colonization by carbapenem-resistant Enterobacterales (OR 16.03, 95% CI 6.5-39.5, P< 0.001); invasive mechanical ventilation (OR 5.6, 95% CI 2.4-13.1, P< 0.001); immunomodulatory agents (tocilizumab/baricitinib) (OR 5.09, 95% CI 2.2-11.8, P< 0.001); C-reactive protein on admission >7 mg/dl (OR 3.59, 95% CI 1.7-7.7, P= 0.001); and previous treatment with piperacillin/tazobactam (OR 2.85, 95% CI 1.1-7.2, P= 0.028). Length of hospital stay was Longer in patients who developed superinfections ompared with those who did not (30 versus 11 days, P< 0.001), while mortality rates were similar (18.8% versus 23.2%, P= 0.445). Conclusions: The risk of bacterial and fungal superinfections in COVID-19 is consistent. Patients who need empiric broad-spectrum antibiotics and immunomodulant drugs should be carefully selected. Infection control rules must be reinforced.
引用
收藏
页码:1078 / 1084
页数:7
相关论文
共 50 条
  • [41] Evaluation of the impact of COVID-19 pandemic on hospital-acquired infections in a tertiary hospital in Malaysia
    Rehab Ismaeil
    Abdul Rahman Fata Nahas
    Norhidayah Binti Kamarudin
    Usman Abubakar
    Mohamad Basri Mat-Nor
    Mohamad Haniki Nik Mohamed
    BMC Infectious Diseases, 23
  • [42] Modeling Patient Risk for Hospital-Acquired Pressure Injuries During COVID-19 A Retrospective Study
    Montgomery, Aoyjai P.
    Patrician, Patricia A.
    Hall, Allyson
    Miltner, Rebecca S.
    Enogela, Ene M.
    Polancich, Shea
    JOURNAL OF NURSING CARE QUALITY, 2022, 37 (02) : 162 - 167
  • [43] Association between tocilizumab treatment of hyperinflammatory patients with COVID-19 in a critical care setting and elevated incidence of hospital-acquired bacterial and invasive fungal infections
    Minihan, B.
    McAuliffe, E.
    Powell, J.
    Wong, S. L.
    Wilkie, K.
    Murphy, C.
    Maher, A.
    Power, L.
    O'Connell, N. H.
    Dunne, C. P.
    JOURNAL OF HOSPITAL INFECTION, 2022, 126 : 29 - 36
  • [44] The impact of the COVID-19 pandemic on hospital-acquired infections at a comprehensive cancer center
    Spallone, A.
    Dib, R. Wilson
    Khawaja, F.
    Chemaly, R.
    SWISS MEDICAL WEEKLY, 2022, 152 : 9S - 10S
  • [45] Nationwide surveillance system to evaluate hospital-acquired COVID-19 in Brazilian hospitals
    de Miranda Costa, M. Machado
    Guedes, A. R.
    Nogueira, M. D. S. P.
    Oliveira, L. S. C.
    Barros, L. de Souza
    Goncalves, M. R. S.
    Carvalho, A. A.
    Amaral de Moura, H. L. C.
    Levin, A. S.
    Oliveira, M. S.
    JOURNAL OF HOSPITAL INFECTION, 2022, 123 : 23 - 26
  • [46] Predictors of Noninvasive Respiratory Support Failure in COVID-19 Patients: A Prospective Observational Study
    Zablockis, Rolandas
    Slekyte, Goda
    Mereskeviciene, Ruta
    Kevelaitiene, Karolina
    Zablockiene, Birute
    Danila, Edvardas
    MEDICINA-LITHUANIA, 2022, 58 (06):
  • [47] Impact of removing the healthcare mask mandate on hospital-acquired COVID-19 rates
    Mehra, R.
    Patterson, B. J.
    Riley, P. A.
    Planche, T. D.
    Breathnach, A. S.
    JOURNAL OF HOSPITAL INFECTION, 2024, 145 : 59 - 64
  • [48] The impact of the COVID-19 pandemic on hospital-acquired infections at a comprehensive cancer center
    Dib, Rita Wilson
    Spallone, Amy
    Khawaja, Fareed
    Feldman, Adina
    Cantu, Sherry
    Chemaly, Roy F.
    AMERICAN JOURNAL OF INFECTION CONTROL, 2023, 51 (12) : 1302 - 1308
  • [49] Risk factors for progressing to critical illness in patients with hospital-acquired COVID-19
    Lee, Kyung-Eui
    Lee, Jinwoo
    Lee, Sang-Min
    Lee, Hong Yeul
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2024, 39 (03): : 477 - 487
  • [50] Prevention of Hospital-Acquired Pressure Injury in COVID-19 Patients in the Prone Position
    Team, Victoria
    Jones, Angela
    Weller, Carolina D.
    INTENSIVE AND CRITICAL CARE NURSING, 2022, 68